Bayer and U.K.-based artificial intelligence (AI) software developer Huma are joining forces to develop AI technology to distinguish different forms of non-small-cell lung cancer (NSCLC) on CT exams.
Making use of Huma's machine-learning experience and Bayer's oncology and medical imaging capabilities, the companies plan to utilize machine-learning technology to spot correlations in molecular and imaging assessments -- such as ground-glass opacities -- that can differentiate types of lung cancers. They will then train and test models to provide accurate diagnoses.
The goal is to quickly identify the patients with certain types of NSCLC who can benefit the most from tailored treatments, according to the firms. Their collaboration will begin immediately.
Bayer's Leaps by Bayer investment arm has been both a series B and series C investor in Huma.
